Supernus Pharmaceuticals (SUPN) Receivables (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Receivables of $216.0 million for Q2 2026, up 47.68% year-over-year from $146.2 million in Q2 2025, and up 17.31% on a QoQ basis from $184.1 million in Q1 2026.
Supernus Pharmaceuticals (SUPN) Receivables (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Receivables for 16 years, with the latest figure at $216.0 million in Q2 2026.
- Receivables for Q2 2026 came in at $216.0 million, up 47.68% year-over-year; the trailing twelve-month figure through Jun 2026 was $216.0 million (up 47.68% YoY), and the FY2025 annual result was $189.6 million, up 29.8% from the prior year.
- Receivables grew to $216.0 million in Q2 2026, from $184.1 million in the prior quarter.
- Over five years, Receivables peaked at $216.0 million in Q2 2026 and troughed at $136.6 million in Q2 2023.
- A 5-year average of $158.7 million and a median of $147.0 million in 2024 frame the typical range for Receivables.
- The widest annual swing landed in 2023, when Receivables slipped 13.61%; it then soared 47.68% in 2026.
- A 5-year view of Receivables shows it stood at $164.1 million in 2022, then slipped by 13.6% to $141.8 million in 2023, then climbed by 3.04% to $146.1 million in 2024, then increased by 29.8% to $189.6 million in 2025, then grew by 13.9% to $216.0 million in 2026.
- Per Business Quant data, the three most recent Receivables figures were $216.0 million in Q2 2026, $184.1 million in Q1 2026, and $189.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | 215.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215.96 Mn |
| Mar 31, 2026 | 184.08 Mn |
| Dec 31, 2025 | 189.60 Mn |
| Sep 30, 2025 | 177.55 Mn |
| Jun 30, 2025 | 146.23 Mn |
| Mar 31, 2025 | 145.64 Mn |
| Dec 31, 2024 | 146.08 Mn |
| Sep 30, 2024 | 145.41 Mn |
| Jun 30, 2024 | 152.49 Mn |
| Mar 31, 2024 | 147.73 Mn |
| Sep 30, 2023 | 141.76 Mn |
| Jun 30, 2023 | 136.56 Mn |
| Mar 31, 2023 | 143.57 Mn |
| Dec 31, 2022 | 165.50 Mn |
| Sep 30, 2022 | 164.09 Mn |
| Jun 30, 2022 | 158.06 Mn |
| Mar 31, 2022 | 145.15 Mn |
| Dec 31, 2021 | 148.93 Mn |
| Sep 30, 2021 | 133.68 Mn |
| Jun 30, 2021 | 137.28 Mn |